Back

Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

29 April 2017 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Rapid Fire 2 - Comorbodities Cardiomyopathies HFA Premium Access Heart Failure 2017 - 4th World Congress on Acute Heart Failure

About the speaker

Photo
Professor David Adams

Le Kremlin-Bicetre Cedex (France)

9 More presentations in this session

Presentation thumbnail
Impact of Iron Deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction.
Doctor P. Martens (Genk, BE)
Abstract Slides Video
Presentation thumbnail
Heart failure and inflammation-related biomarkers as predictors of new onset diabetes in the general population
Doctor N. Suthahar (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- versus post-capillary pulmonary hypertension.
Mr T. Gorter (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Definition of iron deficiency based on the gold standard of bone marrow iron staining and treatment effect of ferric carboxymaltose in heart failure patients
Mr N. Grote Beverborg (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Circulating miRNAs as biomarkers for familial dilated cardiomyopathy
Doctor D. De Gonzalo Calvo (Barcelona, ES)
Abstract

Access the full session

Session thumbnail
Rapid Fire 2 - Comorbodities

The Event

Event poster

Heart Failure 2017 - 4th World Congress on Acute Heart Failure

29 April - 2 May 2017

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources